Investigating Immunotherapy Treatment in Renal Cell Carcinoma

Charles G. Drake, MD, PhD, professor of medical oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting. He debates whether immunotherapies or neoadjuvant therapies would be more useful.

Investigating Immunotherapy Treatment in Renal Cell Carcinoma2018-09-09T10:21:41-04:00

First Ever Kidney Cancer Funding from Congress (CDMRP)

Congressionally-directed Medical Research Program. It took over a decade of hard work from kidney cancer advocates to obtain kidney cancer-specific research funding included in the federal budget. Nevertheless, in March of 2017 Congress approved and the president signed the Consolidation Appropriations Act.

First Ever Kidney Cancer Funding from Congress (CDMRP)2018-07-25T22:15:42-04:00